Zobrazeno 1 - 10
of 893
pro vyhledávání: '"Michael Untch"'
Autor:
Chiara Massa, Thomas Karn, Karsten Weber, Andreas Schneeweiss, Claus Hanusch, Jens Uwe Blohmer, Dirk‐Michael Zahm, Christian Jackisch, Marion van Mackelenbergh, Jörg Thomalla, Frederik Marmé, Jens Huober, Volkmar Müller, Christian Schem, Anja Müller, Elmar Stickeler, Katharina Biehl, Peter A. Fasching, Michael Untch, Sibylle Loibl, Carsten Denkert, Barbara Seliger
Publikováno v:
Clinical and Translational Medicine, Vol 14, Iss 4, Pp n/a-n/a (2024)
Externí odkaz:
https://doaj.org/article/f921f7466a0a4b568dfafa8ea0d35cf6
Autor:
David Krug, Valentina Vladimirova, Michael Untch, Thorsten Kühn, Andreas Schneeweiss, Carsten Denkert, Beyhan Ataseven, Christine Solbach, Bernd Gerber, Hans Tesch, Michael Golatta, Sabine Seiler, Jörg Heil, Valentina Nekljudova, Johannes Holtschmidt, Sibylle Loibl
Publikováno v:
Breast, Vol 74, Iss , Pp 103701- (2024)
Background: Neoadjuvant chemotherapy (NACT) is routinely used for patients with triple-negative breast cancer (TNBC). Upfront breast-conserving therapy (BCT) consisting of breast-conserving surgery (BCS) and adjuvant radiotherapy (RT) has been shown
Externí odkaz:
https://doaj.org/article/8d2a63a4c8bd4f918241d9bea3fb337a
Autor:
Jens Huober, Marion van Mackelenbergh, Andreas Schneeweiss, Fenja Seither, Jens-Uwe Blohmer, Carsten Denkert, Hans Tesch, Claus Hanusch, Christoph Salat, Kerstin Rhiem, Christine Solbach, Peter A. Fasching, Christian Jackisch, Mattea Reinisch, Bianca Lederer, Keyur Mehta, Theresa Link, Valentina Nekljudova, Sibylle Loibl, Michael Untch
Publikováno v:
npj Breast Cancer, Vol 9, Iss 1, Pp 1-12 (2023)
Abstract This retrospective pooled analysis aims to identify factors predicting relapse despite a pathologic complete response (pCR) in patients with breast cancer (BC). 2066 patients with a pCR from five neoadjuvant GBG/AGO-B trials fulfill the incl
Externí odkaz:
https://doaj.org/article/1894262e05954747a7b2989d697dd085
Autor:
Mattea Reinisch, Michael Untch, Rolf Mahlberg, Toralf Reimer, Thomas Hitschold, Frederik Marmé, Mustafa Aydogdu, Sabine Schmatloch, Hans-Joachim Lück, Marcus Schmidt, Ekkehart Ladda, Bruno Valentin Sinn, Peter Klare, Wolfgang Janni, Christian Jackisch, Carsten Denkert, Sabine Seiler, Thomas Göhler, Laura Michel, Nicole Burchardi, Elmar Stickeler, Julia Rey, Nicole Klutinus, Volker Möbus, Sibylle Loibl
Publikováno v:
Breast, Vol 66, Iss , Pp 110-117 (2022)
Background: Trastuzumab given intravenously in combination with chemotherapy is standard of care for patients with early HER2-positive breast cancer (BC). Different randomised studies have shown equivalent efficacy of a subcutaneous injection into th
Externí odkaz:
https://doaj.org/article/916f38f5626a45b9afb718606995934e
Autor:
Dennis J. Slamon, Peter A. Fasching, Sara Hurvitz, Stephen Chia, John Crown, Miguel Martín, Carlos H. Barrios, Aditya Bardia, Seock-Ah Im, Denise A. Yardley, Michael Untch, Chiun-Sheng Huang, Daniil Stroyakovskiy, Binghe Xu, Rebecca L. Moroose, Sherene Loi, Frances Visco, Valerie Bee-Munteanu, Karen Afenjar, Rodrigo Fresco, Tetiana Taran, Arunava Chakravartty, Juan Pablo Zarate, Agnes Lteif, Gabriel N. Hortobagyi
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 15 (2023)
Background: Ribociclib has demonstrated a statistically significant overall survival benefit in pre- and postmenopausal patients with hormone receptor positive/human epidermal growth factor receptor 2 negative (HR+/HER2−) advanced breast cancer. Ne
Externí odkaz:
https://doaj.org/article/73d02bee3f9e4dc6a76bef48c3ed8ce0
Autor:
Sibylle Loibl, Chiun-Sheng Huang, Max S. Mano, Eleftherios P. Mamounas, Charles E. Geyer, Michael Untch, Jean-Christophe Thery, Ingo Schwaner, Steven Limentani, Niklas Loman, Kristina Lübbe, Jenny C. Chang, Thomas Hatschek, David Tesarowski, Chunyan Song, Sanne Lysbet de Haas, Thomas Boulet, Chiara Lambertini, Norman Wolmark
Publikováno v:
npj Breast Cancer, Vol 8, Iss 1, Pp 1-6 (2022)
Abstract Following chemotherapy and human epidermal growth factor 2 (HER2)-targeted neoadjuvant therapy for HER2-positive early breast cancer, residual invasive breast cancer at surgery may be HER2-negative on retesting in some patients. We evaluated
Externí odkaz:
https://doaj.org/article/c268c669d03547e1b3867ec85f83f413
Autor:
Otto Metzger-Filho, Katharine Collier, Sarah Asad, Peter J. Ansell, Mark Watson, Junu Bae, Mathew Cherian, Joyce O’Shaughnessy, Michael Untch, Hope S. Rugo, Jens B. Huober, Mehra Golshan, William M. Sikov, Gunter von Minckwitz, Priya Rastogi, Lang Li, Lijun Cheng, David Maag, Norman Wolmark, Carsten Denkert, W. Fraser Symmans, Charles E. Geyer, Sibylle Loibl, Daniel G. Stover
Publikováno v:
npj Breast Cancer, Vol 7, Iss 1, Pp 1-6 (2021)
Abstract In the BrighTNess trial, carboplatin added to neoadjuvant chemotherapy (NAC) was associated with increased pathologic complete response (pCR) rates in patients with stage II/III triple-negative breast cancer (TNBC). In this matched cohort st
Externí odkaz:
https://doaj.org/article/c6af5c9ea1394c7ab85bf5141ac651b6
Autor:
Melitta Beatrice Köpke, Carl Mathis Wild, Mariella Schneider, Nicole Pochert, Felicitas Schneider, Jacqueline Sagasser, Thorsten Kühn, Michael Untch, Christian Hinske, Matthias Reiger, Claudia Traidl-Hoffmann, Christian Dannecker, Udo Jeschke, Nina Ditsch
Publikováno v:
Cancers, Vol 15, Iss 14, p 3606 (2023)
The collective of the SerMa pilot study included 100 cases of primary breast cancer or Carcinoma in situ who had undergone a mastectomy procedure with or without reconstruction of the breast using an implant or expander at Augsburg University Hospita
Externí odkaz:
https://doaj.org/article/b6daf09bd99f47b38aae5c91646f7528
Autor:
Katya Galactionova, Sibylle Loibl, Paola Salari, Frederik Marmé, Miguel Martin, Michael Untch, Hervé R. Bonnefoi, Sung-Bae Kim, Harry D. Bear, Nicole McCarthy, Karen A. Gelmon, José A. García-Sáenz, Catherine M. Kelly, Toralf Reimer, Masakazu Toi, Hope S. Rugo, Michael Gnant, Andreas Makris, Nicole Burchardi, Matthias Schwenkglenks
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
BackgroundPatients with hormone receptor-positive, HER2-negative breast cancer who have residual invasive disease after neoadjuvant chemotherapy (NACT) are at a high risk of relapse. PENELOPE-B was a double-blind, placebo-controlled, phase III trial
Externí odkaz:
https://doaj.org/article/309493d924a94d99901b52801051e924
Autor:
Andreas Schneeweiss, Johannes Ettl, Diana Lüftner, Matthias W. Beckmann, Erik Belleville, Peter A. Fasching, Tanja N. Fehm, Matthias Geberth, Lothar Häberle, Peyman Hadji, Andreas D. Hartkopf, Carsten Hielscher, Jens Huober, Eugen Ruckhäberle, Wolfgang Janni, Hans Christian Kolberg, Christian M. Kurbacher, Evelyn Klein, Michael P. Lux, Volkmar Müller, Naiba Nabieva, Friedrich Overkamp, Hans Tesch, Elena Laakmann, Florin-Andrei Taran, Julia Seitz, Christoph Thomssen, Michael Untch, Pauline Wimberger, Rachel Wuerstlein, Bernhard Volz, Diethelm Wallwiener, Markus Wallwiener, Sara Y. Brucker
Publikováno v:
Breast, Vol 54, Iss , Pp 88-95 (2020)
Purpose: Treatment with CDK4/6 inhibitors and endocrine therapy (CDK4/6i + ET) is a standard for patients with advanced hormone receptor–positive, HER2-negative (HR + HER2–) breast cancer (BC). However, real-world data on the implementation of th
Externí odkaz:
https://doaj.org/article/06b4953fd7094428a800955c7f592096